Konidaris Tasos 4
4 · Amneal Pharmaceuticals, Inc. · Filed Aug 15, 2025
Insider Transaction Report
Form 4
Konidaris Tasos
Executive Vice President & CFO
Transactions
- Sale
Class A Common Stock
2025-08-14$9.30/sh−119,206$1,108,616→ 341,311 total - Sale
Class A Common Stock
2025-08-13$9.22/sh−161,365$1,487,785→ 460,517 total - Sale
Class A Common Stock
2025-08-15$9.43/sh−219,159$2,066,669→ 122,152 total
Footnotes (3)
- [F1]The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
- [F2]The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.34 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
- [F3]The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $9.47 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.